Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
書誌事項
- 公開日
- 2020-11
- 権利情報
-
- https://www.elsevier.com/tdm/userlicense/1.0/
- https://www.elsevier.com/legal/tdmrep-license
- DOI
-
- 10.1016/s1470-2045(20)30494-0
- 公開者
- Elsevier BV
この論文をさがす
収録刊行物
-
- The Lancet Oncology
-
The Lancet Oncology 21 (11), 1465-1477, 2020-11
Elsevier BV